USA
*Nationwide studies refer to those offered in every US State.
Nationwide • CA • CO • FL • GA • IL • IN • KY • MN • OH • PA • SC • WA • WI •
Outside USA
Alberta • Australia • Canada • Finland • Germany • Italy • New Zealand • Norway • Sweden • United Kingdom •
Click on the study title for more information.
USA
Study Name | Who Can Participate? | | Pathway to Prevention Study (TrialNet) |
To participate in the screening phase of the Pathway to Prevention Study, you must be:
1 to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes; OR
1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandparent with type 1 diabetes.
In general, type 1 diabetes is assumed if it developed before age 40 and required insulin injections within a year of diagnosis.
| | Oral Insulin Study (TrialNet) |
To be screened for the study, you must be:
1 to 45 years of age and have a brother, sister, child, or parent with type 1 diabetes; OR
1 to 20 years of age and have a cousin, aunt, uncle, niece, nephew, half-sibling, or grandparent with type 1 diabetes.
| | Anti-CD3 mAb for Prevention of Type 1 Diabetes in Relatives At Risk (Teplizumab) |
You can be screened for the study if:
You have been referred by TrialNet’s Pathway to Prevention Study
You are 8 to 45 years old (enrollment will initially be limited to people 16-45 years of age)
| | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | Islet Transplantation in Type 1 Diabetes with LEA29Y Maintenance Therapy (CIT-04) |
You may be enrolled into this study, if you:
are 18 to 65 years of age;
have been diagnosed with type 1 diabetes with symptoms prior to age 40;
are insulin dependent for at least 5 years, with three or more injections each day or on insulin pump therapy;
have blood tests that show your body does not make insulin;
are managing your diabetes daily, by checking you blood sugar at least three times a day;
have had at least one episode of severe hypoglycemia in the past year where you needed the help of another person; and
have hypoglycemia unawareness, a condition in which you no longer experience the usual warning signs of hypoglycemia.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | SEARCH for Diabetes in Youth (SEARCH) |
Children and youth who are under age 20 when they were diagnosed with diabetes may be eligible to join. Eligibility may depend on the place the child or young adult resides or the place where health care is received.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Study Name | Who Can Participate? | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
In general, to participate in this study, one must be 18-68 years of age, diagnosed with type 1 diabetes before age 40, be insulin dependent for more than 5 years, and have received a kidney transplant. There are more specific inclusion and exclusion criterion for participation in this study, which can be discussed with the study contact.
| | For additional studies, please click here for a list of studies that are available in every U.S. state. | | Back to Top |
Outside USA
Study Name | Description | | Efficacy of Islet after Kidney Transplantation (CIT-06) |
This study is one of seven studies being conducted by the Clinical Islet Transplant (CIT) Consortium, which is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.
Studies conducted by the CIT Consortium will focus on improving the safety and long-term success of methods for transplanting islets, the insulin-producing cells of the pancreas, in people whose own islets have been destroyed by the autoimmune process that characterizes type 1 diabetes.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Study Name | Description | | Open Label, Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran (LMW-SD) in Islet Transplantation (CIT-01) |
This study is being conducted by the Clinical Islet Transplantation (CIT) Consortium, which is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.
Type 1 diabetes is commonly treated with the administration of insulin, either by multiple insulin injections or by a continuous supply of insulin through a wearable pump. Insulin therapy allows long-term survival in individuals with type 1 diabetes; however, it does not guarantee constant normal blood sugar control. Because of this, long-term type 1 diabetic survivors often develop vascular complications, such as diabetic retinopathy, an eye disease that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that can lead to kidney failure and thus kidney transplant. Some individuals with type 1 diabetes develop hypoglycemia unawareness, a life-threatening condition that is not easily treatable with medication and is characterized by reduced or absent warning signals for hypoglycemia. For such individuals, pancreas or pancreatic islet transplantation are possible treatment options. Rejection of these islets by the recipient's immune system, however, can make the treatment ineffective. An immune response known as instant blood-mediated inflammatory reaction (IBMIR) results in the disruption of islet integrity and islet loss within an hour of transfusion. Low molecular weight sulfated dextran (LMW-SD) inhibits IBMIR by preventing the cascade that triggers it, when combined with pancreatic islets. The purpose of this study is to determine the safety and efficacy of LMW-SD given with islet transfusion, along with immunosuppressive therapy, in people with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Open Label, Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran (LMW-SD) in Islet Transplantation (CIT-01) |
This study is being conducted by the Clinical Islet Transplantation (CIT) Consortium, which is a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.
Type 1 diabetes is commonly treated with the administration of insulin, either by multiple insulin injections or by a continuous supply of insulin through a wearable pump. Insulin therapy allows long-term survival in individuals with type 1 diabetes; however, it does not guarantee constant normal blood sugar control. Because of this, long-term type 1 diabetic survivors often develop vascular complications, such as diabetic retinopathy, an eye disease that can cause poor vision and blindness, and diabetic nephropathy, a kidney disease that can lead to kidney failure and thus kidney transplant. Some individuals with type 1 diabetes develop hypoglycemia unawareness, a life-threatening condition that is not easily treatable with medication and is characterized by reduced or absent warning signals for hypoglycemia. For such individuals, pancreas or pancreatic islet transplantation are possible treatment options. Rejection of these islets by the recipient's immune system, however, can make the treatment ineffective. An immune response known as instant blood-mediated inflammatory reaction (IBMIR) results in the disruption of islet integrity and islet loss within an hour of transfusion. Low molecular weight sulfated dextran (LMW-SD) inhibits IBMIR by preventing the cascade that triggers it, when combined with pancreatic islets. The purpose of this study is to determine the safety and efficacy of LMW-SD given with islet transfusion, along with immunosuppressive therapy, in people with type 1 diabetes.
| | Back to Top |
Study Name | Description | | Pathway to Prevention Study (TrialNet) |
TrialNet is a network of 18 Clinical Centers working in cooperation with screening sites throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia, and New Zealand. This network is dedicated to the study, prevention, and early treatment of type 1 diabetes.
The Natural History Study is one of the studies TrialNet will perform. This study will screen individuals who are close relatives of people with type 1 diabetes to identify those at risk for developing the disease. Individuals at risk will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes. Participants in the Natural History Study may be offered the opportunity to enter into prevention or early treatment studies when these become available.
| | Back to Top |
Return to Type 1 Diabetes Studies Home Page
|
